Safety and efficacy results of the combination of DPX-Survivac, pembrolizumab and intermittent low dose cyclophosphamide (CPA) in subjects with advanced and metastatic solid tumours: Preliminary results from the hepatocellular carcinoma (HCC), NSCLC, bladder cancer, & MSI-H cohorts - Conter, H.J.; MacDonald, L.D.; Fiset, S.; Bramhecha, Y.M.; Chaney, M.; Rosu, G.N. (Annals of oncology, 2019)